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Abstract Autophagy is an essential intracellular self-degradation system, and is known to main-
tain the homeostatic balance between the synthesis, degradation, and recycling of cellular proteins 
and organelles. Recent studies have suggested a possible role of autophagy in systemic sclerosis 
(SSc) ; however, differences in autophagy among pathological phases of SSc have not yet been ex-
amined. Therefore, in the current study we investigated the expression pattern of an autophago-
some marker protein, microtubule-associated protein 1 light chain 3 (LC3) in the lesional skin of a 
murine model and human SSc. In bleomycin-induced mouse scleroderma skin, the number of 
LC3-positive puncta was significantly higher than that in phosphate buffered salts-injected control 
skin after 4 weeks of treatment. Such an increase, however, was not observed in the skin after 2 
weeks of bleomycin treatment, in which few myofibroblasts were detected. In the sclerotic phase 
of SSc patients, the number of LC3-positive puncta in the lower dermis was significantly higher than 
in the upper dermis. It was also significantly higher than in the lower dermis of the control pa-
tients. No increase in LC3-positive puncta was observed in the skin from SSc patients in edema-
tous phase, in which myofibroblasts were hardly detected. These results suggest that changes in 
the autophagic degradation system reflect a skin remodeling process that leads to fibrosis.
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Introduction
Autophagy is an essential intracellular self-deg-
radation system known to maintain the homeostatic 
balance between the synthesis, degradation, and re-
cycling of cellular proteins and organelles1-3). It is 
induced by a variety of stress stimuli, such as nutri-
ent starvation and ischemia, and is initiated by the 
formation of a double membrane structure, called an 
isolation membrane, which elongates to enclose a 
portion of the cytoplasm and/or organelles. When 
the isolation membrane completely closes, it be-
comes an autophagosome, which further acquires ly-
sosomal enzymes by fusion with lysosomes for deg-
radation of its contents, resulting in a structure 
called an autolysosome. Microtubule-associated 
protein 1 light chain 3 (LC3) is an autophagy-related 
gene (Atg) product, and is known to be a marker of 
the isolation membranes, autophagosomes, and a 
fraction of autolysosomes4-7). 
Impairments of autophagy are often associated 
with various diseases, such as malignant tumors, 
heart failure and type 2 diabetes mellitus8-12). Pre-
vious studies have shown that skin specimens from 
systemic sclerosis (SSc) patients have more intense 
LC3 immunoreactivity than those from healthy con-
trols13), whereas another study suggested that SSc 
fibroblasts show impaired autophagy14). Therefore, 
the involvement of autophagy in SSc has not yet 
been fully elucidated. In the present study, we fo-
cused on the differences in the LC3 expression pat-
tern among different phases of SSc progression, and 
investigated the involvement of the autophagy sys-
tem. 
Corresponding author : T. Mori  E-mail : mtatsu@fmu.ac.jp
©2020 The Fukushima Society of Medical Science. This is an open-access article distributed under the terms of 
the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC-BY-NC-SA 4.0). 
https://creativecommons.org/licenses/by-nc-sa/4.0/
17
18 T. Mori et al.
Methods
Animal experiment
Specific pathogen-free C57BL/6J male mice (7 
weeks old) were purchased from CHARLES RIVER 
LABORATORIES JAPAN, Inc. (Kanagawa, Japan), 
and were housed in a controlled environment (21-
24°C, 60% humidity, 12-h light/dark cycle). The 
mice were fed ad libitum (two mice) or starved for 
24 hours (three mice) before being anesthetized by 
intraperitoneal injection of 25 mg/kg pentobarbital 
sodium (Kyoritsu Seiyaku Corporation, Tokyo, Ja-
pan). They were then perfused via the heart, first 
with Ringer’s solution and then with a fixative solu-
tion of 4% paraformaldehyde and 4% sucrose in 
phosphate buffer (pH 7.4). The livers were excised 
and processed for paraffin embedding.
To generate a mouse model for SSc, specific 
pathogen-free C3H/HeJ female mice (6 weeks old) 
were used, as reported previously15,16). The mice 
were purchased from CLEA Japan, Inc. (Tokyo, Ja-
pan), and were housed in a controlled environment 
(21-24°C, 60% humidity, 12-h light/dark cycle), and 
fed ad libitum. The mice were intradermally in-
jected with 50 μg bleomycin (BLM) (Nippon Kayaku 
Co. Ltd., Tokyo, Japan) in phosphate-buffered saline 
(PBS) or PBS alone into the backs once daily for 5 
days per week for 2 or 4 weeks. Five mice were 
used for each group. The mice were anesthetized 
by inhalation of 2.5% isoflurane (Mylan Inc., Tokyo, 
Japan), and skin samples were biopsied from the in-
jected site. These samples were fixed in 10% for-
malin neutral buffer solution (Wako Pure Chemical 
Corporation, Osaka, Japan) overnight and embedded 
in paraffin. All experimental procedures were ap-
proved by the Animal Care and Use Committee of 
Fukushima Medical University (approval numbers 
27016 and 28016).
Human samples
The SSc patients were diagnosed according to 
the SSc diagnostic criteria outlined by the Japanese 
Dermatological Association. The patients included 
were five edematous phase SSc (E-SSc) patients, 
and five sclerotic phase SSc (S-SSc) patients, whose 
clinical characteristics are shown in Table 2. Skin 
samples were biopsied from each patient’s fore-
arm. Control skins were obtained from the edge of 
the resected benign tumors, such as epidermal cyst 
and verruca vulgaris, on the forearms of 5 healthy 
patients (Table 2). All human skin samples were 
fixed in 10% formalin neutral buffer solution (Wako 
Pure Chemical Corporation) overnight and embed-
ded in paraffin. All experimental procedures were 
approved by the Ethics Committee of Fukushima 
Medical University (approval number 2472).
Immunohistological analyses
The paraffin-embedded samples were sectioned 
at 3 μm thickness, then deparaffinized and rehydrat-
ed. For evaluation of skin fibrosis, the sections 
were stained with hematoxylin and eosin (HE), or by 
immunohistochemistry using anti-α smooth muscle 
actin (αSMA) antibody. As demonstrated in a pre-
vious study by Kissin et al., αSMA-positive myofi-
broblasts increase in the skin lesion of SSc pa-
tients17). For the immunohistochemistry, the 
sections were incubated with 3% hydrogen peroxide 
in methanol, and then blocked with 10% normal goat 
serum (Nichirei Biosciences Inc. [Tokyo, Japan], 
426042). Next, the sections were incubated with 
anti-αSMA antibody (Abcam plc [Cambridge, UK], 
ab7817) at a dilution of 1 : 100 in an antibody diluent 
(Roche Diagnostics K.K. [Basel, Switzerland], 251-
018) for 1.5 h at room temperature, followed by in-
cubation with a mixture of peroxidase-conjugated 
goat anti-mouse and anti-rabbit IgGs (Nichirei Bio-
sciences Inc., 424151, Simple Stain MAX PO 
[MULTI]) for 30 min at room temperature. Color 
development was performed using a DAB substrate 
kit (Nichirei Biosciences Inc., 425011). The sec-
tions were then counterstained with hematoxy-
lin. For immunohistofluorescence microscopy 
analysis, the sections were blocked with 5% normal 
donkey serum (Jackson ImmunoResearch Laborato-
ries Inc. [PA, USA], 017-000-121), and incubated 
overnight with rabbit monoclonal antibody against 
LC3A (Abcam plc, ab52768 ; at a dilution of 1 : 400 
in blocking solution), at 4°C. Donkey anti-rabbit 
IgG conjugated with a fluorescent dye, Alexa Fluor 
488 (Jackson ImmunoResearch Laboratories Inc., 
711-545-152) or Alexa Fluor 594 (Jackson Immu-
noResearch Laboratories Inc., 715-585-150), was 
used as a secondary antibody. Hoechst 33342 
(Thermo Fisher Scientific, Inc. [MA, USA], H3570) 
was used for nuclear staining. The sections were 
washed with PBS containing 0.1% Tween-20. They 
were then viewed with a laser scanning confocal mi-
croscope, FV1000 (Olympus, Tokyo, Japan). For 
quantification, five regions of interest (ROI) with a 
size of 105 × 105 μm were randomly captured in the 
dermis of the mice, and in the upper and lower der-
mis of the patients. LC3-positive puncta with a di-
ameter of 0.3-1 μm were counted, then further di-
vided by the number of nuclei in the ROI. The 
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signals of LC3 and nuclei in blood vessels, hair folli-
cles, nerves, and arrector pili muscles were exclud-
ed from this measurement.
Statistical analysis
All data are expressed as a box-and-whisker 
plot, and analyzed using EZR software (version 
1.35 ; Saitama Medical Center, Jichi Medical Univer-
sity, Japan)18). Statistical differences were evaluat-
ed by the Mann-Whitney U test or the Steel Dwass 
test, and values of P < 0.05 were considered statis-
tically significant.
Results
LC3-positive puncta in BLM-treated mouse skin
On observing the HE-stained sections, dermal 
fibrosis was apparent in the 4-week BLM-treated 
mice when compared to the PBS-treated ones, al-
though the fibrosis was less evident in the 2-week 
BLM-treated mice (Figure 1A). More αSMA-
positive myofibroblasts were detected in the dermis 
of the 4-week BLM-treated than the PBS-treated 
mice. Additionally, these myofibroblasts were 
hardly detected in the 2-week BLM-treated mice 
(Figure 1B).
We next examined LC3 distribution by immu-
nohistofluorescence microscopy. The anti-LC3 an-
tibody used in this study was confirmed to detect 
endogenous mouse LC3, because LC3-positive 
puncta increased in the starved mouse livers com-
pared to those in the fed mouse livers (Figure 1C).
Similar puncta were observed in the dermis, 
most markedly in the 4-week BLM-treated mice 
(Table 1, Figure 1D, 1E). Quantitative analysis re-
vealed that the number of LC3-positive puncta was 
significantly higher in the 4-week BLM-treated 
mice (0.117±0.046) than in the 4-week PBS-treated 
mice (0.063±0.036 ; P = 0.032  in Mann-Whitney 
U test, n = 5 ; Figure 1F). There was no signifi-
cant difference between the 2-week BLM- and 
PBS-treated mice. Although the median number 
of LC3-positive puncta in the 4-week BLM-treated 
mice was higher than that in the 2-week BLM-
treated mice, the difference was not statistically sig-
nificant.
LC3-positive puncta in SSc patients
HE-analysis revealed that dermal fibrosis in S-
SSc was more severe than that in E-SSc (Figure 
2A). Regional differences were also evaluated in 
this analysis, because previous studies indicated that 
the lower dermis of SSc patients contains increased 
collagen bundles, fibronectin, and myofibro-
blasts17,19,20). The current study also showed that 
collagen bundles in the lower dermis were denser 
than in the upper dermis in both E-SSc and S-SSc 
samples (Figure 2A). As shown in Figure 2B, nu-
merous αSMA-positive myofibroblasts were ob-
served in the lower dermis of S-SSc samples, but 
they were hardly detected in the upper dermis of 
those samples. Neither were they detected in ei-
ther the lower or upper dermis of the E-SSc sam-
ples. As for LC3-positive puncta, remarkable sig-
nals were observed in the lower dermis of the S-SSc 
samples (Figure 2E), whereas they were weak in the 
dermis of the controls, E-SSc samples, and the up-
per dermis of the S-SSc samples (Figures 2C-
E). There were more LC3-positive puncta in the 
lower dermis of the S-SSc samples (0.854 ± 0.310) 
than in the lower dermis of the controls (0.141 ± 
0.054 ; P = 0.043  in Steel-Dwass test ; Figure 2F) 
or the upper dermis of S-SSc samples (0.264 ± 
0.140 ; P = 0.032  in Mann-Whitney U test ; Figure 
2F). On the other hand, there was no significant 
difference between the upper dermis of the S-SSc 
samples, and the E-SSc samples (0.135 ± 0.067) or 
controls (0.069 ± 0.060).
Discussion
The current study demonstrated a high number 
of LC3-positive puncta in the lesional dermis of 
BLM-treated mice and S-SSc patients compared to 
controls. These results are consistent with those 
of previous studies demonstrating that the tissue 
sections of SSc patients showed more intense LC3 
immunoreactivity than those taken from healthy 
controls13). However, we further advanced this un-
derstanding by demonstrating the differences in re-
gions and degrees of fibrosis. We showed that the 
number of LC3-positive puncta was significantly 
high in severely fibrotic dermis, such as in the lower 
dermis of the S-SSc samples and murine dermis 
treated with BLM for 4 weeks. In contrast, no dif-
ference was observed in mildly fibrotic dermis, such 
as the upper dermis of the S-SSc samples, the der-
mis of the E-SSc samples and the murine dermis 
treated with BLM for 2 weeks. Therefore, these 
results suggest that the autophagy-lysosomal path-
way is closely  correlated with the sclerotic phase, 
where fibrosis proceeds, and that the involvement of 
early immunological changes may be unlikely.
Given that LC3 is localized to the isolation 
membrane, autophagosomes, and a fraction of autol-
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Fig. 1. LC3-positive puncta in the skin of BLM-treated mice
 Mice were treated with PBS or BLM for 2 weeks (2w) or 4 weeks (4w). The skin samples were examined by 
HE staining (A) or immunohistochemistry for αSMA (B). The boxed region is magnified and shown in the in-
set. The arrows indicate αSMA-positive myofibroblasts. Scale bars, 50 μm. Mouse livers with 24-hour star-
vation (Stv) or without (Fed) were processed for immunohistofluorescence microscopy analysis using anti-LC3 
antibody (anti-LC3 ; red) followed by Alexa Fluor 594-conjugated secondary antibody (C). The nuclei were 
stained with Hoechst 33342 (blue). Scale bar, 10 μm. The skin samples from the mice treated with PBS (D) or 
BLM (E) for 2 weeks (2w) or 4 weeks (4w) were immunolabeled using anti-LC3 antibody (anti-LC3 ; green) fol-
lowed by Alexa Fluor 488-conjugated secondary antibody. The nuclei were stained with Hoechst 33342 
(blue). The boxed regions are magnified and shown on the right. The arrows indicate LC3-positive puncta ob-
served in the dermis. Scale bars, 10 μm. LC3-positive puncta (number/nuclei) in ROIs were measured and are 
expressed as a box-and-whisker plot in F. The boxes indicate the upper and lower interquartile range (IQR), the 
lines within the boxes indicate the median, the whiskers indicate the minimum and maximum IQR, and the dot 
indicates the outlier. * : significant difference (P < 0.05 in Mann-Whitney U test).
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ysosomes5-7), the increase in the number of intracel-
lular LC3-positive puncta reflects autophagy activa-
tion and/or the suppression of lysosomal degradation 
of LC3. Therefore, it remains controversial as to 
whether autophagy is really induced or not in SSc 
skin. It has previously been reported that autopha-
gy is activated in BLM-treated mouse lung21-23), 
which is consistent with the present results of 
BLM-induced LC3-positive puncta in the mouse 
skin. Furthermore, previous studies that conduct-
ed knockdown experiments of core Atg genes, Atg5 
or Atg7, as well as pharmacological experiments us-
ing autophagy inhibitors (chloroquine and 3-methyl-
adenine), reported positive roles of autophagy in liv-
er fibrosis24) and the transdifferentiation of cardiac 
myofibroblasts25). Hydroxychloroquine, also an au-
tophagy inhibitor, reduced the metabolic activity and 
suppressed cell proliferation of human fibroblasts26). 
However, it has been reported that SSc fibroblasts 
showed impaired autophagy14), which might promote 
myofibroblast differentiation in idiopathic pulmonary 
fibrosis patients27). These reports suggest that the 
suppression of autophagy occurs in SSc as well as 
other fibrotic conditions. 
Some mechanisms could be considered to link 
such fibrosis with the increase of LC3-positive 
puncta. Transforming growth factor-beta (TGF-
beta) is known to play an important role during fi-
brosis28). Its signaling pathway has been reported 
to increase the mRNA expression of several Atgs, 
such as Beclin 1, Atg5, Atg7, death-associated pro-
tein kinase, and LC3 through both Smad-dependent 
and independent pathways29-31). Therefore, the 
TGF-beta/Smad pathway may cause the increase of 
LC3-positive puncta. Moreover, from a histological 
aspect, severe fibrosis might cause a nutritional in-
sufficiency for fibroblasts in the dermis, which may 
lead to starvation-induced autophagy or somehow 
suppress lysosomal degradation. It is also possible 
that cellular differentiation into myofibroblasts in-
volves autophagy-lysosomal degradation32).
In conclusion, the findings of the current study 
suggest that the autophagy-lysosomal pathway is in-
volved in the sclerotic phase of SSc. There are 
several limitations, such as small sample size, and 
lack of association with disease duration and skin 
sclerosis score in human SSc.  Future studies fo-
cusing on the relationship between the histological 
fibrosis and autophagy-lysosomal system would be 
required to clarify the underling mechanisms of the 
disease progression of SSc.
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Table 1.  The number of LC3-
positive puncta in 
the dermis of the 
mice
Mouse
type
LC3-positive puncta
per cell
PBS 0.064
2 week 0.018
0.054
0.011
0.051
BLM 0.056
2 week 0.088
0.01
0.068
0.026
PBS 0.127
4 week 0.046
0.042
0.044
0.057
BLM 0.158
4 week 0.154
0.068
0.14
0.067
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Fig. 2. LC3-positive puncta in the skin of SSc patients
 E-SSc and S-SSc specimens were examined by HE-staining (A) and immunohistochemistry for αSMA (B). The 
upper (Up) and lower (Lo) regions of the dermis (boxed) are magnified and shown on the bottom half of the im-
age. The arrows in the lower dermis of the S-SSc indicate αSMA-positive myofibroblasts. Scale bars, 100 
μm. The control (C), E-SSc (D) and S-SSc (E) specimens were examined by immunostaining for LC3 (anti-
LC3 ; green) followed by Alexa Fluor 488-conjugated secondary antibody. The upper (Up) and lower (Lo) re-
gions of the dermis are shown. The boxed regions are magnified and shown on the right. The arrows indicate 
LC3-positive puncta observed in the dermis. Scale bars, 10 μm. LC3-positive puncta (number/nuclei) in ROIs 
were measured and are expressed as a box-and-whisker plot in F. The boxes indicate the upper and lower IQR, 
the lines within the boxes indicate the median, the whiskers indicate the minimum and maximum IQR, and the 
dots indicate the outliers. “*1” and “*2” indicate significant difference (P < 0.05) according to the Mann-Whit-
ney U test and Steel Dwass test, respectively.
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